The research progress on the mechanism of Wnt/β-catenin signaling pathway involved in multiple myeloma

doi:10.11958/20220179

Abstract

Abstract:

Multiple myeloma (MM) is a hematological tumor characterized by malignant proliferation of bone marrow plasma cells, and its mechanism of occurrence is closely related to the abnormalities of related signaling pathways. Wnt/β-catenin signaling pathway is involved in the regulation of cell proliferation, differentiation, apoptosis and other biological processes, and it is associated with cell carcinomatosis. In MM, abnormally expressed non-coding RNAs, transcription factors, proteases and secreted proteins can activate the Wnt/β-catenin signaling pathway, thus accelerating the occurrence and development of MM. Therefore, Wnt/β-catenin signaling pathway plays an important role in the pathogenesis of MM. This paper collates and summarizes the research progress of relevant non-coding RNAs, transcription factors, proteases and secretory proteins in MM that affect the Wnt/β-catenin signaling pathway, in order to provide reference for related research.

Key words: multiple myeloma, biomarkers, tumor, Wnt signaling pathway, beta catenin

CLC Number:

R733.3

References 29

[1]	VAN D E, DONK N W C J, PAWLYN C, et al. Multiple myeloma[J]. Lancet, 2021, 397(10272):410-427. doi: 10.1016/S0140-6736(21)00135-5.
[2]	YUAN Y, GUO M, GU C, et al. The role of Wnt/β-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma(review)[J]. Am J Transl Res, 2021, 13(9):9932-9949.
[3]	ANDEL H, KOCEMBA K A, SPAARGAREN M, et al. Aberrant Wnt signaling in multiple myeloma:molecular mechanisms and targeting options[J]. Leukemia, 2019, 33(5):1063-1075. doi: 10.1073/pnas.1618650114.
[4]	DAI Y, GUO X, YANG C. Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β-catenin signaling pathway[J]. Oncol Lett, 2020, 20(2):1295-1299. doi: 10.3892/ol.2020.11678.
[5]	LYBRAND D, BNAIMAN M, LAUMANN J M, et al. Destruction complex dynamics:Wnt/β-catenin signaling alters Axin-GSK3β interactions in vivo[J/OL]. Development, 2019, 146(13):dev164145. doi: 10.1242/dev.164145.
[6]	QI J, LEE H J, SAQUET A, et al. Autoinhibition of dishevelled protein regulated by its extreme C terminus plays a distinct role in Wnt/β-catenin and Wnt/planar cell polarity(PCP) signaling pathways[J]. J Biol Chem, 2017, 292(14):5898-5908. doi: 10.1074/jbc.M116.772509.
[7]	GUO B, XIAO C, LIU Y, et al. MiR-744-5p inhibits multiple myeloma proliferation,epithelial mesenchymal transformation and glycolysis by targeting SOX12/Wnt/β-Catenin signaling[J]. Onco Targets Ther, 2021(14):1161-1172. doi: 10.2147/OTT.S270636.
[8]	LIU Q, RAN R, SONG M, et al. LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β‐catenin/cyclin D1 signaling via PLAGL2[J]. Cell Biol Toxicol, 2021. doi: 10.1007/s10565-021-09628-7. ［Epub ahead of print］.
[9]	ZHOU F, WANG D, ZHOU N, et al. Circular RNA protein tyrosine kinase 2 promotes cell proliferation,migration and suppresses apoptosis via activating microRNA-638 mediated MEK/ERK,Wnt/β-catenin signaling pathways in multiple myeloma[J]. Front Oncol, 2021(11):648189. doi: 10.3389/fonc.2021.648189.
[10]	DESANTIS V, SOLIMANDO A G, SALTARELLA I, et al. MicroRNAs as a potential new preventive approach in the transition from asymptomatic to symptomatic multiple myeloma disease[J]. Cancers(Basel), 2021, 13(15):3650. doi: 10.3390/cancers13153650.
[11]	XIANG P, YEUNG Y T, WANG J, et al. miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition[J]. Int J Cancer, 2021, 148(12):3071-3085. doi: 10.1002/ijc.33528.
[12]	王椋, 徐敏, 邢健, 等. MiR-144调控Wnt4/β-catenin信号通路抑制MM细胞恶性生物学行为的研究[J]. 中国实验血液学杂志, 2020, 28(4):1256-1260.
	WANG L, XU M, XING J, et al. MiR-144 inhibits the malignant biologic behaviors of multiple myeloma cells by regulating Wnt4/β-catenin signaling pathway[J]. Journal of Experimental Hematology, 2020, 28(4):1256-1260. doi: 10.19746/j.cnki.issn.1009-2137.2020.04.029.
[13]	GOWDA P S, WILDMAN B J, TROTTER T N, et al. Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progression[J]. Mol Cancer Res, 2018, 16(7):1138-1148. doi: 10.1158/1541-7786.
[14]	WU Z, ZHANG Y, YANG Z, et al. Elevation of miR-302b prevents multiple myeloma cell growth and bone destruction by blocking DKK1 secretion[J]. Cancer Cell Int, 2021, 21(1):187. doi: 10.1186/s12935-021-01887-y.
[15]	CHEN H, ZHAO Y, ZHANG J, et al. Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway[J]. Cytokine, 2021, 142:155495. doi: 10.1016/j.cyto.2021.155495.
[16]	ZHOU M, CHEN J, ZHANG H, et al. KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p[J]. Int J Biol Sci, 2020, 16(12):2063-2071. doi: 10.7150/ijbs.45999.
[17]	CUI Y S, SONG Y P, FANG B J. The role of long non-coding RNAs in multiple myeloma[J]. Eur J Haematol, 2019, 103(1):3-9. doi: 10.1111/ejh.13237.
[18]	CHEN R, ZHANG X, WANG C. LncRNA HOXB-AS1 promotes cell growth in multiple myeloma via FUT4 mRNA stability by ELAVL1[J]. J Cell Biochem, 2020, 121(10):4043-4051. doi: 10.1002/jcb.29573.
[19]	GENG W, GUO X, ZHANG L, et al. Resveratrol inhibits proliferation,migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway[J]. Biomed Pharmacother, 2018, 107:484-494. doi: 10.1016/j.biopha.2018.08.003.
[20]	PEREZ DE ACHA O, ROSSI M, GOROSPE M. Circular RNAs in blood malignancies[J]. Front Mol Biosci, 2020, 7:109. doi: 10.3389/fmolb.2020.00109.
[21]	GAO Y, LI L, HOU L, et al. SOX12 promotes the growth of multiple myeloma cells by enhancing Wnt/β-catenin signaling[J]. Exp Cell Res, 2020, 388(1):111814. doi: 10.1016/j.yexcr.2020.111814.
[22]	LV M, LIU Q. JMJD2C triggers the growth of multiple myeloma cells via activation of β-catenin[J]. Oncol Rep, 2021, 45(3):1162-1170. doi: 10.3892/or.2021.7934.
[23]	VAN ANDEL H, KOCEMBAR K A, DE HAAN-KRAMER A, et al. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease[J]. Oncogene, 2017, 36(15):2105-2115. doi: 10.1038/onc.2016.368.
[24]	REN Z, VAN ANDEL H, DE LAU W, et al. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins[J]. Blood, 2018, 131(9):982-994. doi: 10.1182/blood-2017-07-797050.
[25]	REN Z, SPAARGAREN M, PALS S T. Syndecan-1 and stromal heparan sulfate proteoglycans:key moderators of plasma cell biology and myeloma pathogenesis[J]. Blood, 2021, 137(13):1713-1718. doi: 10.1182/blood.2020008188.
[26]	LIU X, PENG J, ZHOU Y, et al. Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β-catenin signaling pathway[J]. Mol Med Rep, 2019, 20(3):2159-2166. doi: 10.3892/mmr.2019.10465.
[27]	FENG Y, ZHANG Y, WEI X, et al. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma[J]. Cancer Biomark, 2019, 24(2):195-201. doi: 10.3233/CBM-181909.
[28]	COLUCCI S, BRUNETTI G, ORANGER A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion[J]. Blood Cancer J, 2011, 1(6):e27. doi: 10.1038/bcj.2011.22.
[29]	MCDONALD M M, REAGAN M R, YOULTEN S E, et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma[J]. Blood, 2017, 129(26):3452-3464. doi: 10.1182/blood-2017-03-773341.